Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Brian M. Kopec"'
Autor:
Mohammad Norouzi, Vinith Yathindranath, James A. Thliveris, Brian M. Kopec, Teruna J. Siahaan, Donald W. Miller
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-18 (2020)
Abstract Although doxorubicin (DOX) is an effective anti-cancer drug with cytotoxicity in a variety of different tumors, its effectiveness in treating glioblastoma multiforme (GBM) is constrained by insufficient penetration across the blood–brain b
Externí odkaz:
https://doaj.org/article/48789dff986642a393532b6e887ac3be
Publikováno v:
Pharmaceutics, Vol 11, Iss 11, p 568 (2019)
Many proteins can be used to treat brain diseases; however, the presence of the blood−brain barrier (BBB) creates an obstacle to delivering them into the brain. Previously, various molecules were delivered through the paracellular pathway of the BB
Externí odkaz:
https://doaj.org/article/9b00799caef84923b0000fec990ab487
Autor:
Babu V. Sajesh, Ngoc H. On, Refaat Omar, Samaa Alrushaid, Brian M. Kopec, Wei-Guang Wang, Han-Dong Sun, Ryan Lillico, Ted M. Lakowski, Teruna J. Siahaan, Neal M. Davies, Pema-Tenzin Puno, Magimairajan Issai Vanan, Donald W. Miller
Publikováno v:
Pharmaceutics, Vol 11, Iss 9, p 481 (2019)
The blood-brain barrier (BBB) poses a major obstacle by preventing potential therapeutic agents from reaching their intended brain targets at sufficient concentrations. While transient disruption of the BBB has been used to enhance chemotherapeutic e
Externí odkaz:
https://doaj.org/article/25cc141381be4297a117030ee6ead52b
Publikováno v:
Mol Pharm
It is very challenging to develop protein drugs for the treatment of brain diseases; this is due to the difficulty in delivering them into the brain because of the blood-brain barrier (BBB). Thus, alternative delivery methods need further exploration
Autor:
Brian M. Kopec, Teruna J. Siahaan, Donald W. Miller, James A. Thliveris, Mohammad Norouzi, Vinith Yathindranath
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-18 (2020)
Scientific Reports
Scientific Reports
Although doxorubicin (DOX) is an effective anti-cancer drug with cytotoxicity in a variety of different tumors, its effectiveness in treating glioblastoma multiforme (GBM) is constrained by insufficient penetration across the blood–brain barrier (B
Publikováno v:
Med Res Arch
Neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) have been demonstrated for their potential as a neuroregenerative treatment of Alzheimer’s disease (AD). Unfortunately, most proteins cannot be effe
Publikováno v:
Mol Pharm
The number of FDA-approved protein drugs (biologics), such as antibodies, antibody–drug conjugates, hormones, and enzymes, continues to grow at a rapid rate; most of these drugs are used to treat diseases of the peripheral body. Unfortunately, most
Publikováno v:
Blood-Brain Barrier ISBN: 9781493989454
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fbebe38cee8ee8a727f37731803a312
https://doi.org/10.1007/978-1-4939-8946-1_2
https://doi.org/10.1007/978-1-4939-8946-1_2
Publikováno v:
Advances in experimental medicine and biology. 1030
Peptides have been used as drugs to treat various health conditions, and they are also being developed as diagnostic agents. Due to their receptor selectivity, peptides have recently been utilized for drug delivery to target drug molecules to specifi
Autor:
Ogar Ichire, Verónica Gómez-Pérez, Caden Mackenzie, Rosario Diaz-Gonzalez, Guiomar Pérez-Moreno, ThanhTruc Pham, Francisco Gamarro, Brian M. Kopec, Miguel Navarro, Madeline Walden, Marika Pitot, Raquel García-Hernández, Christopher Butler, Henry Zecca, Gloria Ceballos-Pérez, Dolores González-Pacanowska, Emma Krakoff, Amy B. Dounay, Luis Miguel Ruiz
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
In 2014, a published report of the high-throughput screen of>42,000 kinase inhibitors from GlaxoSmithKline against T. brucei identified 797 potent and selective hits. From this rich data set, we selected NEU-0001101 (1) for hit-to-lead optimization.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36882c24e80fb4e724bf97391ab253ba
https://europepmc.org/articles/PMC6214665/
https://europepmc.org/articles/PMC6214665/